The following table represents a summary of prescription drug changes in the market from Q1 2024 (January through March) that may potentially be seen in workers' compensation. These could be new drug approvals, new generics, withdrawals and discontinuations of certain products, as well as near-term pipeline products and patent expirations. There may be other labeled or off-label uses for these products that may or may not be supported by medical treatment guidelines.
In some cases, there may not be an exact date listed, so the assumption would be that the approval or patent expiration would be at some point during the listed month, quarter or year. For discontinued medications, dispensing may still continue until pharmacies have exhausted their existing supply. Anticipated approval dates and availability of generics are subject to final FDA approval. Please note that these lists are not all-inclusive.
If you have any questions, please contact your Clinical Account Executive or another member of your account team.
Workers’ Compensation Prescription Drug Updates
Recent Generic Launches | ||
---|---|---|
Brand Name (Generic Name) | Indication/Use | Launch Date |
Indocin® (indomethacin) | Pain/Inflammation | January 12, 2024 |
Gralise® (gabapentin once daily) 300 mg and 600 mg tablet | Pain/Inflammation | January 29, 2024 |
Discontinuation and Withdrawals | ||
---|---|---|
Medication | Indication/Use | Discontinuation Date |
Zorvolex™ (diclofenac capsule) | Pain/Inflammation | January 2, 2024 |
Oxaydo® (oxycodone tablet) | Pain | January 30, 2024 |
New Drug Pipeline | ||
---|---|---|
Medication | Indication/Use | Anticipated Approval |
Livervant (diazepam film) | Seizures | April 28, 2024 |
naloxone intranasal | Opioid Overdose | July 15, 2024 |
midomafetamine | Post-Traumatic Stress Disorder | August 11, 2024 |
Neffy (epinephrine nasal spray) | Anaphylaxis | October 2, 2024 |
ansofaxine | Depression | 2024 |
Omlyclo (omalizumab biosimilar) | Asthma | March 10, 2025 |
Patent Expirations | ||
---|---|---|
Brand Name (Generic Name) | Indication/Use | Patient Expiration |
Prialt® (ziconotide intrathecal) | Pain | October 1, 2024 |
Flovent HFA (fluticasone propionate) | Asthma | 2024 |
Isentress® 400 mg (raltegravir) | HIV/Post-Exposure Prophylaxis (PEP) | 2024 |
Rayos® (prednisone delayed release) | Inflammation | 2024 |